Table 4 Subgroup analysis: intention-to-treat (ITT) excluding five re-enrolled patients.

From: Tasimelteon safely and effectively improves sleep in Smith–Magenis syndrome: a double-blind randomized trial followed by an open-label extension

 

Placebo (N = 20)

Tasimelteon (N = 20)

Difference

p value

DDSQ50

0.1

0.6

0.5

0.0056

Total DDSQ

0.1

0.5

0.4

0.0053

DDTST50 (minutes)

6.3

29.7

23.4

0.0083

Total DDTST (minutes)

6.2

33.0

26.8

0.0028

  1. DDSQ average daily diary sleep quality, DDSQ50 average 50% worst daily diary sleep quality, DDTST average daily diary total sleep time, DDTST50 average 50% worst daily diary total sleep time.
Back to article page